TYMS and cancer: Additionally, TS is a target of 5-fluorouracil (5-FU), an anticancer chemotherapeutic agent used in the treatment of various human cancers [15] and closely associated with intratumoral expression of TS [16], which is significantly correlated with proliferative activity and poor prognosis in patients with NSCLC [17].